Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Use of Targeted Therapy in the Treatment of Advanced Cutaneous Cancers

Use of Targeted Therapy in the Treatment of Advanced Cutaneous Cancers Opinion EDITORIAL Use of Targeted Therapy in the Treatment of Advanced Cutaneous Cancers M. Laurin Council, MD Now is an exciting time in the field of cutaneous oncology. More gins, whenever possible, is recommended. In addition, senti- nel lymph node biopsy is recommended in all cases where advances in the treatment of metastatic melanoma, ad- vanced basal and squamous cell carcinomas, and Merkel cell nodes are not clinically or radiologically enlarged. Postopera- carcinoma have been made in the past 5 years than in the pre- tive adjuvant irradiation is used to decrease recurrence rates. vious 5 decades. As in other Patients with positive sentinel lymph nodes, or nodes that are fields of oncology, the discov- clinically or radiologically suspect, undergo additional lymph Related article page 505 ery of targeted therapies has node dissection and irradiation and are enrolled in clinical trials revolutionized our treat- where offered. This is why the distinction between a primary ment of patients with advanced disease. Older cytotoxic agents Merkel cell carcinoma and a cutaneous metastasis is so criti- with substantial morbidity have been replaced with thera- cal. A second primary tumor should be treated with a wide ex- pies directed at specific aberrant pathways http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Use of Targeted Therapy in the Treatment of Advanced Cutaneous Cancers

JAMA Dermatology , Volume 153 (6) – Jun 12, 2017

Loading next page...
 
/lp/american-medical-association/use-of-targeted-therapy-in-the-treatment-of-advanced-cutaneous-cancers-nOg1MRSMYg

References (11)

Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2017.0506
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Use of Targeted Therapy in the Treatment of Advanced Cutaneous Cancers M. Laurin Council, MD Now is an exciting time in the field of cutaneous oncology. More gins, whenever possible, is recommended. In addition, senti- nel lymph node biopsy is recommended in all cases where advances in the treatment of metastatic melanoma, ad- vanced basal and squamous cell carcinomas, and Merkel cell nodes are not clinically or radiologically enlarged. Postopera- carcinoma have been made in the past 5 years than in the pre- tive adjuvant irradiation is used to decrease recurrence rates. vious 5 decades. As in other Patients with positive sentinel lymph nodes, or nodes that are fields of oncology, the discov- clinically or radiologically suspect, undergo additional lymph Related article page 505 ery of targeted therapies has node dissection and irradiation and are enrolled in clinical trials revolutionized our treat- where offered. This is why the distinction between a primary ment of patients with advanced disease. Older cytotoxic agents Merkel cell carcinoma and a cutaneous metastasis is so criti- with substantial morbidity have been replaced with thera- cal. A second primary tumor should be treated with a wide ex- pies directed at specific aberrant pathways

Journal

JAMA DermatologyAmerican Medical Association

Published: Jun 12, 2017

There are no references for this article.